Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature

Virology

Volumn 422, Issue 2, 2012, Pages 174-184

  Sabo, Michelle C ^a   Luca, Vincent C ^a   Ray, Stuart C ^b   Bukh, Jens ^c,d   Fremont, Daved H ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antibody; Hepatitis C; Neutralization; Structure; Virion

Indexed keywords

EPITOPE; GLYCOPROTEIN E2; MONOCLONAL ANTIBODY;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGH TEMPERATURE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INCUBATION TEMPERATURE; INCUBATION TIME; LOW TEMPERATURE; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS ATTACHMENT; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; CELL LINE; EPITOPES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; KINETICS; TEMPERATURE; TIME FACTORS;

HEPATITIS C VIRUS;

EID: 84855194867     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.10.023     Document Type: Article

References (67)

1. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., Poordad F., Goodman Z.D., Sings H.L., Boparai N., Burroughs M., Brass C.A., Albrecht J.K., Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1207-1217.
2. Bankwitz D., Steinmann E., Bitzegeio J., Ciesek S., Friesland M., Herrmann E., Zeisel M.B., Baumert T.F., Keck Z.Y., Foung S.K., Pecheur E.I., Pietschmann T. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 2010, 84:5751-5763.
3. Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J., Pascale S., Scarselli E., Cortese R., Nicosia A., Cosset F.L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 2003, 278:41624-41630.
4. Bartosch B., Verney G., Dreux M., Donot P., Morice Y., Penin F., Pawlotsky J.M., Lavillette D., Cosset F.L. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 2005, 79:8217-8229.
5. Bertaux C., Dragic T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J. Virol. 2006, 80:4940-4948.
6. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
7. Ciesek S., Friesland M., Steinmann J., Becker B., Wedemeyer H., Manns M.P., Pietschmann T., Steinmann E. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. J. Infect. Dis. 2010, 201:1859-1866.
8. Cox A.L., Netski D.M., Mosbruger T., Sherman S.G., Strathdee S., Ompad D., Vlahov D., Chien D., Shyamala V., Ray S.C., Thomas D.L. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin. Infect. Dis. 2005, 40:951-958.
9. Diamond M.S., Pierson T.C., Fremont D.H. The structural immunology of antibody protection against West Nile virus. Immunol. Rev. 2008, 225:212-225.
10. Dowd K.A., Pierson T.C. Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 2011, 411:306-315.
11. Dowd K.A., Netski D.M., Wang X.H., Cox A.L., Ray S.C. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009, 136:2377-2386.
12. Dowd K.A., Jost C.A., Durbin A.P., Whitehead S.S., Pierson T.C. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of west Nile virus. PLoS Pathog. 2011, 7:e1002111.
13. Dreux M., Pietschmann T., Granier C., Voisset C., Ricard-Blum S., Mangeot P.E., Keck Z., Foung S., Vu-Dac N., Dubuisson J., Bartenschlager R., Lavillette D., Cosset F.L. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 2006, 281:18285-18295.
14. Farci P., Shimoda A., Wong D., Cabezon T., De Gioannis D., Strazzera A., Shimizu Y., Shapiro M., Alter H.J., Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:15394-15399.
15. Forns X., Payette P.J., Ma X., Satterfield W., Eder G., Mushahwar I.K., Govindarajan S., Davis H.L., Emerson S.U., Purcell R.H., Bukh J. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000, 32:618-625.
16. Gastaminza P., Dryden K.A., Boyd B., Wood M.R., Law M., Yeager M., Chisari F.V. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J. Virol. 2010, 84:10999-11009.
17. Goffard A., Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie 2003, 85:295-301.
18. Goffard A., Callens N., Bartosch B., Wychowski C., Cosset F.L., Montpellier C., Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 2005, 79:8400-8409.
19. Gubler D.J., Kuno G., Markoff L. Flaviviruses. Fields Virology 2007, 1154-1251. Lippincott Williams & Wilkins, Philadelphia, PA. D.M. Knipe, P.M.H., D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
20. Haberstroh A., Schnober E.K., Zeisel M.B., Carolla P., Barth H., Blum H.E., Cosset F.L., Koutsoudakis G., Bartenschlager R., Union A., Depla E., Owsianka A., Patel A.H., Schuster C., Stoll-Keller F., Doffoel M., Dreux M., Baumert T.F. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008, 135(1719-1728):e1711.
21. Hadlock K.G., Lanford R.E., Perkins S., Rowe J., Yang Q., Levy S., Pileri P., Abrignani S., Foung S.K. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 2000, 74:10407-10416.
22. Helle F., Vieyres G., Elkrief L., Popescu C.I., Wychowski C., Descamps V., Castelain S., Roingeard P., Duverlie G., Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J. Virol. 2010, 84:11905-11915.
23. Houghton M., Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005, 436:961-966.
24. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
25. Kim C.S., Keum S.J., Jang S.K. Generation of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature. PLoS One 2011, 6:e22808.
26. Klasse P.J., Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 2002, 83:2091-2108.
27. Krey T., d'Alayer J., Kikuti C.M., Saulnier A., Damier-Piolle L., Petitpas I., Johansson D.X., Tawar R.G., Baron B., Robert B., England P., Persson M.A., Martin A., Rey F.A. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 2010, 6:e1000762.
28. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
29. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., Sakellariou G., Intrator L., Bartosch B., Pawlotsky J.M., Cosset F.L. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 2005, 79:6023-6034.
30. Law M., Maruyama T., Lewis J., Giang E., Tarr A.W., Stamataki Z., Gastaminza P., Chisari F.V., Jones I.M., Fox R.I., Ball J.K., McKeating J.A., Kneteman N.M., Burton D.R. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 2008, 14:25-27.
31. Lewis J.K., Bothner B., Smith T.J., Siuzdak G. Antiviral agent blocks breathing of the common cold virus. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6774-6778.
32. Li Q., Yafal A.G., Lee Y.M., Hogle J., Chow M. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature. J. Virol. 1994, 68:3965-3970.
33. Lindebach B.D., Thiel H.J., Rice C.M. Flaviviridae: the viruses and their replication. Fields Virology 2007, 1102-1151. Lippincott Williams & Wilkins, Philadelphia PA. 5 ed. D.M. Knipe, P.M.H., D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
34. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
35. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., Feinstone S.M., Alter H., Rice C.M., McKeating J.A. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10149-10154.
36. Lok S.M., Kostyuchenko V., Nybakken G.E., Holdaway H.A., Battisti A.J., Sukupolvi-Petty S., Sedlak D., Fremont D.H., Chipman P.R., Roehrig J.T., Diamond M.S., Kuhn R.J., Rossmann M.G. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 2008, 15:312-317.
37. McCaffrey K., Boo I., Poumbourios P., Drummer H.E. Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding. J. Virol. 2007, 81:9584-9590.
38. Meunier J.C., Russell R.S., Engle R.E., Faulk K.N., Purcell R.H., Emerson S.U. Apolipoprotein c1 association with hepatitis C virus. J. Virol. 2008, 82:9647-9656.
39. Meunier J.C., Gottwein J.M., Houghton M., Russell R.S., Emerson S.U., Bukh J., Purcell R.H. Vaccine-Induced Cross-Genotype Reactive Neutralizing Antibodies Against Hepatitis C Virus. J. Infect. Dis. 2011, 204:1186-1190.
40. Netski D.M., Mosbruger T., Depla E., Maertens G., Ray S.C., Hamilton R.G., Roundtree S., Thomas D.L., McKeating J., Cox A. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 2005, 41:667-675.
41. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005, 437:764-769.
42. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., Chung K.M., Ebel G.D., Kramer L.D., Fremont D.H., Diamond M.S. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 2005, 11:522-530.
43. Oliphant T., Nybakken G.E., Engle M., Xu Q., Nelson C.A., Sukupolvi-Petty S., Marri A., Lachmi B.E., Olshevsky U., Fremont D.H., Pierson T.C., Diamond M.S. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 2006, 80:12149-12159.
44. Osburn W.O., Fisher B.E., Dowd K.A., Urban G., Liu L., Ray S.C., Thomas D.L., Cox A.L. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010, 138:315-324.
45. Owen D.M., Huang H., Ye J., Gale M. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009, 394:99-108.
46. Owsianka A., Clayton R.F., Loomis-Price L.D., McKeating J.A., Patel A.H. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 2001, 82:1877-1883.
47. Owsianka A.M., Tarr A.W., Keck Z.Y., Li T.K., Witteveldt J., Adair R., Foung S.K., Ball J.K., Patel A.H. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 2008, 89:653-659.
48. Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Fremont D.H., Diamond M.S. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 2007, 1:135-145.
49. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
50. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy K.R., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J.P. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1195-1206.
51. Puig M., Major M.E., Mihalik K., Feinstone S.M. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 2004, 22:991-1000.
52. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280:1949-1953.
53. Ruprecht C.R., Krarup A., Reynell L., Mann A.M., Brandenberg O.F., Berlinger L., Abela I.A., Regoes R.R., Gunthard H.F., Rusert P., Trkola A. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J. Exp. Med. 2011, 208:439-454.
54. Sabo M.C., Luca V., Prentoe J., Hopcraft S.E., Blight K.J., Yi M., Lemon S.M., Ball J.K., Bukh J., Evans M.J., Fremont D.H., Diamond M.S. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a post-attachment step. J. Virol. 2011, 85:7005-7019.
55. Scarselli E., Ansuini H., Cerino R., Roccasecca R.M., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002, 21:5017-5025.
56. Scheel T.K., Gottwein J.M., Jensen T.B., Prentoe J.C., Hoegh A.M., Alter H.J., Eugen-Olsen J., Bukh J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:997-1002.
57. Stiasny K., Kiermayr S., Holzmann H., Heinz F.X. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 2006, 80:9557-9568.
58. Strickland G.T., El-Kamary S.S., Klenerman P., Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect. Dis. 2008, 8:379-386.
59. Tarr A.W., Owsianka A.M., Timms J.M., McClure C.P., Brown R.J., Hickling T.P., Pietschmann T., Bartenschlager R., Patel A.H., Ball J.K. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 2006, 43:592-601.
60. Thomas A.A., Vrijsen R., Boeye A. Relationship between poliovirus neutralization and aggregation. J. Virol. 1986, 59:479-485.
61. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 2006, 80:1734-1741.
62. Vieyres G., Thomas X., Descamps V., Duverlie G., Patel A.H., Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J. Virol. 2010, 84:10159-10168.
63. von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., McKeating J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132:667-678.
64. Weiner A.J., Brauer M.J., Rosenblatt J., Richman K.H., Tung J., Crawford K., Bonino F., Saracco G., Choo Q.L., Houghton M., et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991, 180:842-848.
65. Yu X., Qiao M., Atanasov I., Hu Z., Kato T., Liang T.J., Zhou Z.H. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology 2007, 367:126-134.
66. Zeuzem S., Feinman S.V., Rasenack J., Heathcote E.J., Lai M.Y., Gane E., O'Grady J., Reichen J., Diago M., Lin A., Hoffman J., Brunda M.J. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000, 343:1666-1672.
67. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., Focaccia R., Younossi Z., Foster G.R., Horban A., Ferenci P., Nevens F., Mullhaupt B., Pockros P., Terg R., Shouval D., van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011, 364:2417-2428.